ILMN - イルミナ （Illumina Inc.） イルミナILMNのチャート
ILMNの企業情報
| symbol | ILMN |
|---|---|
| 会社名 | Illumina Inc （イルミナ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 イルミナ(Illumina Inc.)は遺伝子解析用シーケンシングおよびアレイベースのソリューションを提供する。同社は2つの事業を運営する。Core Illuminaと連結変動持分事業体（VIE）事業は、GRAIL Inc. (GRAIL)とHelix Holdings I LLC (Helix)の運営を含む。Core Illuminaは核心事業を含む。その製品とサービスは、研究、臨床及び応用市場で顧客にサービスを提供し、多様なゲノムソリューションの採用を可能にする。同社の統合システム、消耗品及び分析ツールのポートフォリオは、ゲノムの複雑さ、価格ポイント、およびスループットに対応し、顧客が研究または臨床上の課題に対してソリューションを選択できるようにする。同社は、非侵襲的な出生前検査（NIPT）、着床前の遺伝的スクリーニングと診断、並びに新生児および遺伝的健康検査を含む、生殖医療ソリューションを提供している。 イルミナは、遺伝学および健康についての理解を推進する為の統合的なソリュ―ションのプロバイダ―。遺伝的変異および遺伝子機能の大規模解析を行うための包括的なライフサイエンスツ―ルとシステムの開発、製造、販売を行う。顧客は世界中のさまざまな学術機関、政府機関、製薬企業、バイオテクノロジ―企業、および他の主要な機関を含む。 at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. |
| 本社所在地 | 5200 Illumina Way San Diego CA 92122 USA |
| 代表者氏名 | Jay T. Flatley ジェイ・T・フラットリー |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 858-202-4500 |
| 設立年月日 | 35886 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 6200人 |
| url | www.illumina.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ilmn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 120 |
| 終値（lastsale） | 326.07 |
| 時価総額（marketcap） | 47932290000 |
| 時価総額 | 時価総額（百万ドル） 4625.7 |
| 売上高 | 売上高（百万ドル） 3103 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 44861.7 |
| 当期純利益 | 当期純利益（百万ドル） 798.00000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 01 July 2018 Illumina Inc. revenues increased 28% to $1.61B. Net income decreased 16% to $417M. Revenues reflect Consolidated VIEs segment increase of 100% to $6M. Basic Earnings per Share excluding Extraordinary Items decreased from $3.39 to $2.84. |
ILMNのテクニカル分析
ILMNのニュース
House Republicans seek information from FTC over Illumina''s Grail takeover 2023/06/08 17:49:06 Seeking Alpha
House Republicans are renewing a call for the Federal Trade Commission to provide it information over its review of Illumina''s planned $7.1 billion takeover of cancer screening test…
Rocky history of Illumina''s Grail deal 2023/06/06 18:12:21 Investing.com
https://www.investing.com/news/stock-market-news/rocky-history-of-illuminas-grail-deal-3099468
Apple''s Upcoming VR Headset Marks Significant New Product Debut In Almost 10 Years, Regulators Want Tighter Capital Requirements For Large US Banks, Software Configuration Error at Grail Causes Cancer Misdiagnosis: Today''s Top Stories 2023/06/05 13:45:46 Benzinga
Wall Street Journal Megabanks Beware: Regulatory Big Brother Wants a Tighter Leash Amid Recent Bank Failures U.S. regulators are reportedly gearing up to enforce stricter measures on large banks to enhance their financial stability following a series of failures among midsize banks earlier this year. People familiar with the plans have indicated that the proposed changes could result in an average increase of approximately 20% in overall capital requirements for larger banks. The specific amount will depend on each bank''s business activities, with the most significant increases expected for U.S. megabanks with substantial trading operations. Get Ready For Apple''s WWDC: Software Updates and First New Significant Product In a Decade Apple Inc (NASDAQ: AAPL ) prepares to showcase its VR headset, marking its first significant new product in nearly a decade, on Monday at its annual developer conference. The rest of the conference focuses on software providers making applications in the Apple ecosystem.
Illumina unit Grail in hot water over erroneous cancer results – FT 2023/06/02 19:38:07 Seeking Alpha
Over 400 patients who opted for early cancer detection tests developed by Illumina (ILMN) subsidiary Grail received erroneous letters last month indicating that they may have…
Illumina names Hologic CEO as chair, elects Edwards CFO to board 2023/06/02 14:32:37 Seeking Alpha
Illumina''s (ILMN) board has elected Hologic (HOLX) CEO Stephen MacMillan as its new non-executive chair and Edwards Lifesciences (EW) CFO Scott Ullem as an independent director.
The Market Continues To Underprice Illumina''s Stock And Its Genomics Leadership 2023/06/01 08:54:23 Seeking Alpha
Illumina is undervalued by 23% according to a discounted cash flow analysis, with a fair value of $253.94. Read why ILMN stock is a Buy.
Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin By Reuters 2023/05/31 01:08:28 Investor Daily Updates
2/2 © Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake 2/2 By Svea Herbst-Bayliss NEW YORK (Reuters) – Illumina Inc (NASDAQ:) CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more […] The post Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin By Reuters first appeared on Forex Trader Hub .
Illumina CEO survived Icahn''s challenge by more than 2-to-1 margin 2023/05/30 22:46:39 Investing.com
https://www.investing.com/news/stock-market-news/illumina-ceo-survived-icahns-challenge-by-more-than-2to1-margin-3094287
Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin 2023/05/30 22:36:39 Financial Post
NEW YORK — Illumina Inc CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday. While the outcome of the vote was known, the tally had […]
Insider trades & hedge fund moves: Carl Icahn tosses out Illumina chair 2023/05/30 07:42:05 Investing.com
https://www.investing.com/news/stock-market-news/insider-trades--hedge-fund-moves-carl-icahn-tosses-out-illumina-chair-3093037
Tracking COVID-19 With Dust at the Ohio State University 2022/10/18 17:10:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 18, 2022 / When COVID-19 hit, most of The Ohio State University-home of the Buckeyes in the state capital of Columbus-shut down. But the Applied Microbiology Services Laboratory (ASML) within its Infectious Diseases Institute (IDI) stayed open. "The Buckeyes are amazing students," says Seth Faith, who serves as the executive director for the Center of Microbiome Science and strategic alliance officer for IDI, but also supervises the lab. "A lot of them are hungry and passionate. At least one individual working in the lab had family in Wuhan, China, and they hadn''t seen their family for two years. They wanted to be a part of solving this pandemic." Over the next two years or so, AMSL employed 88 lab workers at various times, who administered more than 850,000 PCR diagnostic tests for COVID-19, with an average turnaround time of 8.75 hours. Meanwhile, an OSU professor named Karen Dannemiller had been going into homes and businesses looking for toxic chemicals in the built environment.
Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB 2022/10/18 10:53:32 Seeking Alpha
Illumina (ILMN) and GenoScreen are collaborating to expand access to genomic testing for multidrug-resistant ((MDR)) tuberculosis ((TB)) in an effort to end the disease…
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis 2022/10/18 10:00:00 PR Newswire
Transformative alliance will help advance the World Health Organization''s strategy to end the global TB epidemic by 2035 SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative…
Boosting STEM Education in Bangladesh 2022/10/17 13:10:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 17, 2022 / Illumina and the Illumina Corporate Foundation have provided a grant to the Child Health Research Foundation (CHRF), a Bangladeshi nonprofit that promotes public health and STEM education. The grant, worth over $300,000, includes cash and in-kind product. The grant will support CHRF''s Building Scientists for Bangladesh program , which will introduce young women in under-resourced communities around the country to science and provide hands-on genomic training for university students and early career professionals. Bangladesh faces a multifaceted problem: Disease burden is high, and access and exposure to STEM education and the benefits and practice of science remain low. To complicate matters further, Bangladeshi universities are experiencing a significant decline in STEM enrollment, particularly among women. CHRF director Senjuti Saha, PhD, and her team hope to counteract this discouraging trend. "We believe that everyone across the world should have equal access to the practice and benefits of science and that if more young women completing high school can see themselves as scientists addressing problems in their communities, they will be encouraged to pursue STEM," says Saha, who is spearheading the education program. "To make science more relatable to their everyday lives-not limited to theories they read about in textbooks-our researchers will take science to high schools across the country, especially in rural communities, and perform easy-to-do experiments to engage students and teachers." The Mission CHRF has been working in Bangladesh since the 1980s because pediatric infections were causing far too many preventable deaths.
In Our DNA: Suzanne Rohrback, Senior Staff Bioinformatics Scientist at Illumina 2022/10/14 13:45:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 14, 2022 / Illumina: As a scientist on Illumina''s Assay Research team in San Diego, Suzanne Rohrback works with colleagues to come up with new ways next-generation sequencing (NGS) can maximize insights from a sample-such as cells from a tumor or a tube of blood-extracting as much information about it as possible, as efficiently as possible. Specifically, Rohrback''s role is in bioinformatics; she works closely with her coworkers who perform experiments, turning their hypotheses into code and graphs that build a deep understanding of the system at hand. As she puts it: "I''m a data detective! I''m always asking, ‘What''s different between these samples and why did it change?'' Answering this teaches us how biology works and identifies warning signals that could help doctors and scientists understand, diagnose, or treat disease." Rohrback was an early member of the team that developed the Illumina COVIDSeq™ Test , a high-throughput, sequencing-based, in vitro diagnostic workflow that enables the detection of SARS-CoV-2. "Everything went from zero to 60 in an instant," she says. "I''ve never been so hyper-focused or felt so purposeful and connected to so many coworkers across the globe-many of whom I''d never met.